沙美特罗/福替卡松治疗中重度慢性阻塞性肺疾病稳定期临床观察

Clinical observation of salmeterol/foticasone in the treatment of moderate and severe chronic obstructive pulmonary disease in stable stage

目的慢性阻塞性肺疾病不仅对患者呼吸系统影响较大,还可合并多种肺外疾病,严重威胁患者健康。本研究分析沙美特罗/福替卡松在中重度慢性阻塞性肺疾病稳定期的临床应用效果。方法选择北票市中心医院2017-03-01-2019-02-28收治的86例中重度慢性阻塞性肺疾病患者作为研究对象,依据患者入院顺序奇偶性将其交叉分为对照组与研究组。对照组给予氨茶碱治疗,研究组在对照组治疗基础上增加沙美特罗/福替卡松治疗,比较两组治疗效果、肺功能改善情况和生活质量评分。结果研究组治疗有效率为97.67%,高于对照组的79.07%,χ^2=7.242,P=0.007。治疗后,研究组1秒用力呼气容积(1.87±0.43)L,高于对照组的(1.45±0.36)L,t=3.349,P=0.002;研究组1秒用力呼气容积/预计值为(65.84±7.16)%,高于对照组的(52.93±6.29)%,t=6.058,P<0.001;研究组1秒用力呼气容积与用力肺活量的比值为(73.42±8.13)%,高于对照组的(59.36±7.45)%,t=5.702,P<0.001;研究组6min步行距离为(382.18±30.47)m,长于对照组的(335.12±25.73)m,t=5.277,P<0.001。治疗后,研究组圣·乔治呼吸疾病问卷生存质量评分为(31.86±2.63)分,显著低于对照组的(38.49±3.11)分,t=7.280,P<0.001。结论中重度慢性阻塞性肺疾病稳定期患者应用沙美特罗/福替卡松治疗,可以有效提升临床治疗效果,改善患者肺功能,提升其生存质量。

OBJECTIVE The chronic obstructive pulmonary disease(COPD)not only has a great impact on the respiratory system,but also can be combined with extrapulmonary diseases.It seriously threatens the health and safety of patients.The study aims to analyze the effect of salmeterol/fosticasone in stable stage of severe COPD.METHODS A total of 86 patients with moderate to severe COPD admitted to Beipiao Central Hospital from March 1,2017to February 28,2019 were selected as the study subjects.They were divided into control group and research group according to the hospitalization order.The control group was treated with aminophylline.Salmeterol/Foticasone was added to the research group on the basis of the control group.The curative effect,pulmonary function and quality of life scores were compared between the two groups.RESULTS The effective rate of the research group was 97.67%,significantly higher than that of the control group(79.07%),χ^2=7.242,P=0.007.After treatment,the FEV1of the research group was(1.87±0.43)L,higher than that of the control group(1.45±0.36)L,t=3.349,P=0.002.The FEV1/predicted value of the research group was(65.84±7.16)%,higher than that of the control group(52.93±6.29)%,t=6.058,P<0.001.The FEV1/FVC value of the research group was(73.42±8.13)%,higher than that of the control group(59.36±7.45)%,t=5.702,P<0.001.The 6-minute walking distance of the research group was(382.18±30.47)m.higher than that of the control group(335.12±25.73)m,t=5.277,P<0.001.After treatment,the quality of life score of St.George′s respiratory disease questionnaire in the research group was(31.86±2.63),lower than that of the control group(38.49±3.11),t=7.280,P<0.001.CONCLUSION Salmeterol/Foticasone can improve the curative effect in patients with severe COPD in stable stage,improve the lung function of patients and improve their quality of life.